Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618080 · ClinicalTrials.gov registry record
LGMD R1 Natural History Study
A clinical trial of Limb Girdle Muscular Dystrophy and LGMD2A, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 12
- Study locations
NCT05618080 is a study of Limb Girdle Muscular Dystrophy and LGMD2A that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 100 participants, below the 223-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT05618080, a study of Limb Girdle Muscular Dystrophy and LGMD2A, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Conditions Studied
Study Locations (12)
Other
- Leiden University Medical Center - Leiden
- Newcastle University - Newcastle upon Tyne
California
- University of California, Irvine - Orange
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- University of Florida - Gainesville
Indiana
- The Community Health Clinic, Inc. - Shipshewana
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Minnesota
- University of Minnesota, Department of Neurology - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2028-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05618080
The ClinicalTrials.gov registry entry for NCT05618080 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (55% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Limb Girdle Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05618080 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05618080 about?
NCT05618080 is a clinical study titled "LGMD R1 Natural History Study". This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
What is the current status of trial NCT05618080?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-01-31. Estimated completion is 2028-08.
What conditions does trial NCT05618080 study?
This clinical trial studies the following conditions: Limb Girdle Muscular Dystrophy, LGMD2A, Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy Type R1.
Who is sponsoring clinical trial NCT05618080?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05618080 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limb Girdle Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
RECRUITING · Phase 1
-
Molecular Analysis of Patients With Neuromuscular Disease
RECRUITING
-
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
ACTIVE NOT RECRUITING · Phase 1
-
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
ACTIVE NOT RECRUITING
-
Biomarker Development in LGMD2i
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.